As cardiovascular disease(CVD)incidence and mortality rates continue to rise in China,the importance of identifying and managing CVD risk factors grows.Obstructive sleep apnea(OSA)is a prevalent sleep-related breathing disorder,affecting an estimated 936 million individuals aged 30-69 worldwide,with China leading globally with 176 million affected.Increasing research indicates a close association between OSA and the onset and progression of various CVD,significantly affecting outcomes.However,OSA has long been underrecognized and undertreated in CVD clinical practice.To address this,National Expert Commission for Cardiovascular Diseases,Cardiovascular Group,Chinese Academy Society of Sleep Medicine,Chinese Medical Doctor Association,and Geriatric Sleep Disorders and Cardiopulmonary Group,Division of Sleep Science and Technology,China Association of Gerontology and Geriatrics convened multidisplinary experts to formulate the"Expert Consensus on the Evaluation and Management of Obstructive Sleep Apnea in Patients With Cardiovascular Diseases(2024 Edition)".This consensus addresses core clinical issues such as screening,diagnosis,treatment,and follow-up of CVD patients with OSA.It offers 17 recommendations on common clinical questions,based on current evidence-based medicine,following extensive discussions and votes,aiming to standardize the assessment and management of OSA in Chinese CVD patients,support clinical decision-making,and improve clinical care and service quality.